Cargando…
Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2
Virus-like particles (VLPs) offer great potential as a safe and effective vaccine platform against SARS-CoV-2, the causative agent of COVID-19. Here, we show that SARS-CoV-2 VLPs can be generated by expression of the four viral structural proteins in a mammalian expression system. Immunization of mi...
Autores principales: | Resch, Matthew D., Wen, Ke, Mazboudi, Ryan, Mulhall Maasz, Hannah, Persaud, Mirjana, Garvey, Kaitlyn, Gallardo, Leslie, Gottlieb, Paul, Alimova, Aleksandra, Khayat, Reza, Morales, Jorge, Bielefeldt-Ohmann, Helle, Bowen, Richard A., Galarza, Jose M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782034/ https://www.ncbi.nlm.nih.gov/pubmed/36560407 http://dx.doi.org/10.3390/vaccines10121997 |
Ejemplares similares
-
A recombinant virus-like particle vaccine against adenovirus-7 induces a potent humoral response
por: Mazboudi, Ryan, et al.
Publicado: (2023) -
Novel and efficient method for the reconstruction of adenoviruses through isothermal assembly and its potential applications
por: Wen, Ke, et al.
Publicado: (2023) -
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023) -
Comparative analysis of the immunogenicity of monovalent and multivalent rotavirus immunogens
por: Mi, Kai, et al.
Publicado: (2017) -
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
por: Hultqvist, Greta, et al.
Publicado: (2017)